FDA approval of Eli Lilly's Zepbound is a win for patients as Ozempic competitors boom
Pharmaceutical companies are now racing to develop anti-obesity drugs, and experts say that could drive supply up, and price down. The U.S. Food and Drug Administration (FDA) announced Wednesday th...
Eli Lilly Shares Hit All-Time High After FDA Approves Drug for Weight-Loss Treatment
Eli Lilly (LLY) shares hit an all-time high Wednesday after the Food and Drug Administration (FDA) approved the drug maker's Zepbound injection to treat people who are obese or are overweight and a...
Eli Lilly's Zepbound has a strong shot of being the biggest drug of all time: Guggenheim's Fernandez
Guggenheim analyst Seamus Fernandez joins 'Power Lunch' to discuss Eli Lilly's latest drug to get FDA approval, whether it'll become the biggest-selling drug of all time, and who will be on the hoo...
FDA Approves Diabetes Drug Mounjaro For Weight Loss Under Brand Name Zepbound
Eli Lilly's Zepbound helped users lose up to 22.5% of their weight in clinical trials.
UK's MHRA authorises Eli Lilly's Mounjaro
Britain's health regulator on Wednesday authorised Eli Lilly's diabetes drug Mounjaro for weight management and weight loss in the UK.
What to know about Eli Lilly's new obesity drug
The U.S. Food and Drug Administration approved Eli Lilly's keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's popular weight-loss therapy Wegovy.
LLY stock jumps after FDA approves Eli Lilly's tirzepatide drug for weight loss
Eli Lilly And Co's (NYSE: LLY) stock saw a notable surge, trading at $610.50, up 1.69% (+$10.14) today, following the Food and Drug Administration's (FDA) approval of their blockbuster drug tirzepa...
Eli Lilly Wins FDA Approval For Highly Anticipated Weight-Loss Drug
The FDA approved a highly anticipated weight-loss drug from Eli Lilly on Wednesday. Eli Lilly stock rose less than 2% after the release.
U.S. FDA approves Lilly's weight-loss drug
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's drug for weight loss, according to data on the agency's website, giving the drugmaker entry into a lucrative market that has ...
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?
Eli Lilly now forecasts that it will have lower profits this year than previously projected. Usually, announcements of that type take the wind out of a stock's price.
Eli Lilly chief scientific officer ‘extremely optimistic' that major new Alzheimer's breakthrough is coming
Dr. Daniel Skovronsky believes a big leap in Alzheimer's disease treatment may be just around the corner–and that an overlooked class of medicines could become the GLP-1 drugs of the future.
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.
Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham
Geoff Meacham, Bank of America senior pharmaceutical analyst, joins 'The Exchange' to discuss Eli Lilly's performance, the demand outlook for weight loss drugs, and more.
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.
Related Companies